ABBV - Ironwood Pharma falls 7% as Linzess Q2 sales of drug from AbbVie weigh

• Ironwood Pharmaceuticals ( NASDAQ: IRWD ) is trading down 7% after AbbVie ( ABBV ) Friday morning reported Q2 2022 revenue of Linzess (linaclotide) -- which is marketed by both companies -- that came in below analyst consensus estimates.
• Linzess and Constella (linaclotide's trade name in Europe, Canada, and Mexico) brought in revenue of $255M in the quarter, below the consensus of $276.2M. That was a 4.5% drop from the year-ago period.
• Ironwood reports its Q2 earnings on August 4 with a consensus revenue estimate of $103.5M .
• Seeking Alpha's Quant Rating views ( IRWD ) as a hold with strong grades for profitability and momentum .

For further details see: